Table 1

Demographic, clinical and histological characteristics of the patient cohort
Treatment group
DMARDs RTX
Number of patients 22 19
Age (years) 43 (30 to 56) 40 (27 to 53)
Sex (female) 22 (100%) 18 (94.7%)
Disease duration (months) 14 (7 to 21) 13 (6 to 20)
Parotid gland enlargement 18 (81.8%) 16 (84.2%)
Cutaneous vasculitis 2 (9.0%) 3 (15.7%)
Pulmonary involvement 1 (4.5%) 1 (5.2%)
Neurological involvement 3 (13.6%) 2 (10.5%)
Renal involvement 0 (0%) 0 (0%)
Autoimmune cytopenia 7 (31.8%) 8 (42.1%)
Myositis 0 (0%) 0 (0%)
Arthritis. 11 (50%) 9 (47.3%)
Lymphadenopathy 15 (68.1%) 17 (89.4%)
ESSDAI 19.8 (6 to 41) 20.3 (6 to 41)
Prednisonea 22 (12.5) 19 (12.5)
DMARDs (HCQ/MTX/CsA) 22 (15/13/8) 0 (0/0/0)
Chisholm and Mason score ≥3 22 19
Focus score 1.8 (1 to 3.3) 1.8 (1 to 3.4)

Data presented as mean (range) or number (%) unless otherwise stated. CsA, cyclosporine; DMARDs, disease-modifying anti-rheumatic drugs; HCQ, hydroxychloroquine; MTX, methotrexate; RTX, rituximab. aData presented as number of patients (mean dose in milligrams).

Carubbi et al.

Carubbi et al. Arthritis Research & Therapy 2013 15:R172   doi:10.1186/ar4359

Open Data